OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
GFCM59

Genesis Fertility Center PCL

Healthcare Facilities & ServicesVerified

Genesis Fertility Center PCL maintains a strong liquidity position with a current ratio of 2.77 and cash and equivalents of 130.75 million THB, indicating sufficient short-term financial flexibility. The company's debt-to-equity ratio is 0.05, reflecting a conservative capital structure with minimal leverage. Return on equity (ROE) stands at 3.95%, and return on assets (ROA) is 3.34%, both below the typical thresholds for high-margin healthcare services, suggesting room for improvement in asset utilization and profitability. The company's operating income of 34.76 million THB and net income of 22.40 million THB indicate modest profitability, with a gross margin of 41.7% (147.16 million THB gross profit on 352.99 million THB revenue). These figures suggest the company is generating stable but not exceptional returns, which may be typical for a fertility services provider in a price-sensitive market. Genesis Fertility Center PCL operates through a network of clinics and subsidiaries, including Genosomics Company Limited and GFC Fertility Group Company Limited, and serves both domestic and international patients. The company's revenue is not disclosed by segment or geography, but its international patient base suggests some geographic diversification. The company's revenue of 352.99 million THB reflects a stable operating model, though no specific growth trajectory is provided in the data. Capital expenditures of -41.59 million THB suggest a focus on cost control or asset optimization rather than expansion. Analysts have assigned a single "Hold" recommendation, with no strong buy or buy ratings, indicating a neutral outlook. The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The absence of dilution risk is supported by the fact that basic and diluted shares outstanding are equal at 220 million shares, and no recent equity issuance or ATM/shelf disclosures are noted. No recent filings or transcripts are provided in the data to indicate material events or strategic shifts.

30-day price · GFCM(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyGenesis Fertility Center PCL
TickerGFCM.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Genesis Fertility Center PCL provides fertility and reproductive healthcare services, including IVF, ICSI, and IUI, to domestic and international patients through its network of clinics and subsidiaries.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Genesis Fertility Center PCL maintains a strong liquidity position with a current ratio of 2.77 and cash and equivalents of 130.75 million THB, indicating sufficient short-term financial flexibility. The company's debt-to-equity ratio is 0.05, reflecting a conservative capital structure with minimal leverage. Return on equity (ROE) stands at 3.95%, and return on assets (ROA) is 3.34%, both below the typical thresholds for high-margin healthcare services, suggesting room for improvement in asset utilization and profitability. The company's operating income of 34.76 million THB and net income of 22.40 million THB indicate modest profitability, with a gross margin of 41.7% (147.16 million THB gross profit on 352.99 million THB revenue). These figures suggest the company is generating stable but not exceptional returns, which may be typical for a fertility services provider in a price-sensitive market. Genesis Fertility Center PCL operates through a network of clinics and subsidiaries, including Genosomics Company Limited and GFC Fertility Group Company Limited, and serves both domestic and international patients. The company's revenue is not disclosed by segment or geography, but its international patient base suggests some geographic diversification. The company's revenue of 352.99 million THB reflects a stable operating model, though no specific growth trajectory is provided in the data. Capital expenditures of -41.59 million THB suggest a focus on cost control or asset optimization rather than expansion. Analysts have assigned a single "Hold" recommendation, with no strong buy or buy ratings, indicating a neutral outlook. The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The absence of dilution risk is supported by the fact that basic and diluted shares outstanding are equal at 220 million shares, and no recent equity issuance or ATM/shelf disclosures are noted. No recent filings or transcripts are provided in the data to indicate material events or strategic shifts.
Key takeaways
  • Genesis Fertility Center PCL maintains a conservative capital structure with a low debt-to-equity ratio of 0.05 and strong liquidity.
  • The company's ROE of 3.95% and ROA of 3.34% suggest modest returns, below typical thresholds for high-margin healthcare services.
  • The company serves both domestic and international patients, though revenue concentration by geography is not disclosed.
  • Analysts have assigned a single "Hold" recommendation, with no strong buy or buy ratings, indicating a neutral outlook.
  • The company has no immediate liquidity or dilution risks, with no filing-based flags detected.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$353.0M
Gross profit$147.2M
Operating income$34.8M
Net income$22.4M
R&D
SG&A
D&A
SBC
Operating cash flow$63.9M
CapEx-$41.6M
Free cash flow-$4.3M
Total assets$671.3M
Total liabilities$103.7M
Total equity$567.7M
Cash & equivalents$130.7M
Long-term debt$30.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$567.7M
Net cash$100.7M
Current ratio2.8
Debt/Equity0.1
ROA3.3%
ROE4.0%
Cash conversion2.9%
CapEx/Revenue-11.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricGFCMActivity
Op margin9.8%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin6.3%8.6% medp25 6.3% · p75 12.4%below median
Gross margin41.7%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue-11.8%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity5.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Observations
IR observations
Mean price target3.50 THB
Median price target3.50 THB
High price target3.50 THB
Low price target3.50 THB
Mean recommendation3.50 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count1.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate0.12 THB
Last actual EPS0.10 THB
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 12:42 UTC#2329ac4e
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 12:45 UTCJob: 0817ab15